title: PrEP trial successes prompt cost-effectiveness questions.
authors: Roxanne
authors: R
authors: Khamsi
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy / Q000517:prevention & control*; D003362:Cost-Benefit Analysis / Q000706:statistics & numerical data*; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D004338:Drug Combinations; D000069480:Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; D006801:Humans; D009943:Organophosphorus Compounds / Q000191:economics* / Q000627:therapeutic use*
chemical_list: D004338:Drug Combinations; D000069480:Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; D009943:Organophosphorus Compounds; D003841:Deoxycytidine